The latest announcement is out from Allergy Therapeutics ( (GB:AGY) ).
Allergy Therapeutics has announced the publication of successful results from their G306 Phase III trial for Grass MATA MPL in the journal Allergy. The trial demonstrated a 20.3% reduction in symptoms compared to placebo, surpassing the efficacy of other similar treatments in the past decade. This new treatment, requiring only six injections, offers a significant improvement in quality of life for patients and positions Allergy Therapeutics as a leader in innovative allergy solutions.
More about Allergy Therapeutics
Allergy Therapeutics is a fully integrated commercial biotechnology company that specializes in allergy immunotherapies. The company focuses on developing innovative treatments for allergy sufferers, with a particular emphasis on subcutaneous immunotherapy for conditions like allergic rhinoconjunctivitis caused by grass pollen.
YTD Price Performance: -4.00%
Average Trading Volume: 496,124
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £297.4M
See more data about AGY stock on TipRanks’ Stock Analysis page.